Buy MXiPr Powder: Premium Research Product

Overview

MXiPr Powder is the abbreviation for Methoxisopropamine. It is also known as Isopropyloxetamine, Isopropyxetamine, or by the structural identifier 3-MeO-2′-Oxo-PCiPr.

Forensic authorities in Slovenia first identified MXiPr in late 2020. It belongs to the arycyclohexylamine class of compounds, the same chemical family as ketamine and the designer substance methoxetamine (MXE).

The Chemistry Behind MXiPr

To understand MXiPr, it helps to look at MXE, a designer dissociative that became popular in the early 2010s before many countries banned it.

MXiPr is the N-isopropyl homologue of MXE. In simple terms, chemists modified the MXE molecule by replacing an ethyl group with an isopropyl group.

Manufacturers typically produce MXiPr in unregulated laboratories, where it appears as a white or off-white crystalline powder. Because it closely resembles many other powdered substances, visual inspection alone cannot identify it. Instead, laboratories rely on analytical techniques such as gas chromatography-mass spectrometry (GC-MS) for accurate identification.

How MXiPr Interacts with the Brain

MXiPr primarily acts as an NMDA receptor antagonist.

By blocking NMDA receptors, MXiPr disrupts the activity of glutamate, one of the brain’s main excitatory neurotransmitters. As a result, communication between the brain and the body changes significantly, producing dissociative effects.

Although clinical research remains very limited, user reports and early toxicological observations describe several common effects, including:

Deep dissociation – A strong feeling of detachment from the body or surroundings.
Sensory distortion – Visual and auditory changes, along with an altered sense of time.
Reduced motor control – Loss of coordination (ataxia) and decreased sensitivity to pain.

Potential Health Risks

Because MXiPr is a novel psychoactive substance (NPS), researchers have very little clinical data on its effects in humans. However, toxicologists have raised several concerns based on its similarity to other arylcyclohexylamines.

Potency and Accidental Overdose

MXiPr is highly potent in powder form. Consequently, even small measuring errors may produce unexpectedly strong effects. At higher amounts, users may experience profound immobilization and become unable to respond to environmental hazards or seek assistance during a medical emergency.

Unpredictable Behaviour

Although higher amounts often produce sedation, related compounds have also caused confusion, agitation, and excessive physical activity during the early stages of intoxication or at lower amounts.

Long-Term Organ Toxicity

Furthermore, MXiPr shares its core chemical structure with ketamine. For this reason, healthcare professionals suspect that repeated exposure may carry similar risks of bladder and urinary tract damage, including ketamine-associated cystitis.

Current Legal Status

Authorities across the UK and Europe have introduced restrictions on MXiPr because of public health concerns.

United Kingdom

Under the Misuse of Drugs Act 1971, UK legislation broadly covers many arylcyclohexylamine compounds. As a result, MXiPr is treated as a Class B controlled drug, making unauthorized possession, supply, and importation criminal offences.

Europe

Across Europe, many countries have also restricted MXiPr.

In Germany, the compound falls under the New Psychoactive Substances Act (NpSG), which limits its use to authorised scientific and industrial research. In addition, countries including Hungary and Sweden have introduced their own restrictions to prevent unregulated distribution.

Summary

MXiPr is a relatively new arylcyclohexylamine that shares structural similarities with ketamine and MXE. It primarily acts by blocking NMDA receptors, producing dissociative effects and altered perception. However, researchers still know very little about its long-term safety. Because of its potency and uncertain risk profile, authorities throughout the UK and Europe have introduced strict legal controls, limiting its use to authorised research settings.

where to find MXiPr Powder York

MXiPr Powder